Table of Contents
1. Website
- 1.1 The URL address of official journal web site is j-nn.org.
-
1.2 ‘Aims & Scope’ statement: It aims to offer the recent advances about all aspects of ultrasound
and neuroimaging in the field of stroke, cerebrovascular or other neurological diseases for clinicians and researchers that will improve knowledge of clinical practice, education, and academic research. The JNN offers full coverage of all the relevant stroke or cerebrovascular aspects of neurosonology including transcranial Doppler, carotid duplex ultrasound, peripheral ultrasound, and of neuroimaging such as MRI, CT, SPECT, or PET. Specifically, the JNN includes neuroimaging marker or sign (i.e., atherosclerosis, small-vessel disease, acute ischemia, etc.) related studies associated with predicting outcome. It is also interested in the field of peripheral neuropathy based on ultrasound or imaging. Basic sciences can be welcome if the results are closely relevant to clinical practice.
-
1.3 Readership: It is primarily for scientific journal editors and staffs who works for scientific journals. Its readership can be expanded to other positions: • Professors on neurosciences can access and adopt a variety of data for education • Neurologists are able to read recent advance or can get the recent update for the better knowledge.
-
1.4 Authorship criteria: Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Every author should meet all of these four conditions. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. Copyright assignment may be completed by a first author or corresponding author on behalf of all of authors after an approval.
Corresponding author and first author: The JNN does not allow multiple corresponding authors for one article. Only one author should correspond with the editorial office and readers for one article. The JNN does accept notice of equal contribution for the first author when the study was clearly performed by co-first authors. Correction of authorship after publication: The JNN does not correct authorship after publication unless a mistake has been made by the editorial staff. Authorship may be changed before publication but after submission when an authorship correction is requested by all of authors involved with a manuscript.
-
1.5 Duplicate submission and redundant publication: Submitted manuscripts must not have been previously published or be under consideration for publication elsewhere. No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. Submitted manuscripts are screened for possible plagiarism or duplicate publication by CrossCheck upon arrival. If plagiarism or duplicate publication related to the papers of this journal is detected, the manuscripts may be rejected, the authors will be announced in the journal, and their institutions will be informed. There will also be penalties for the authors. A letter of permission is required for any and all material that has been published previously. It is the responsibility of the author to request permission from the publisher for any material that is being reproduced. This requirement applies to text, figures, and tables.
- 1.6 pISSN: 2635-425X eISSN: 2635-4357
2. Name of Journal
The official journal title is Journal of Neurosonology and Neuroimaging. Abbreviated title is J Neurosonol Neuroimag.
3. Peer Review Process
The JNN reviews all manuscripts received. A manuscript is first reviewed for its format and adherence to the aims and scope of the journal. If the manuscript meets these two criteria, it is dispatched to two or three investigators in the field with relevant knowledge. After the manuscript is sent to reviewers, JNN waits to receive opinions from reviewers. In addition, if deemed necessary, a review of statistics may be requested. The authors’ names and affiliations are removed during a peer review. The acceptance criteria for all papers are based on the quality and originality of the research and its scientific significance. Acceptance of the manuscript is decided based on the critiques and recommended decision of the reviewers. An initial decision will normally be made no later than 4 weeks of receipt of a manuscript, and the reviewers’ comments are sent to the corresponding author by E-mail. The corresponding author must indicate the alterations that have been made in response to the reviewers’ comments point-by-point. Failure to resubmit the revised manuscript within 8 weeks of the editorial decision may be regarded as a withdrawal. A final decision on acceptance/rejection for publication is forwarded to the corresponding author from the editor. All manuscripts from editors, employees, or members of the editorial board are processed same to other unsolicited manuscripts. During the review process, submitters will not engage in the decision process. Editors will not handle their own manuscripts although they are commissioned ones. We neither guarantee the acceptance without review nor noticeably short peer review times for unsolicited manuscripts. Commissioned manuscript is also reviewed before publication. The JNN adopts double-blind peer review in which case, not only authors but also reviewers do not know each other. It is not allowed that the submitted manuscript is sent to a reviewer whose institution is same with the author.
4. Ownership and Management
4.1 Information about the ownership: This journal is owned by the publisher, the Korean Society of Neurosonology Editors.
4.2 JNN Management Team
Editor-in-Chief |
Jong-Ho Park |
Sungkyunkwan University, Korea |
Manuscript Editor |
Da Bin Park |
Jin Publishing Co., Seoul, Korea |
Layout Editor |
Mi Jung Kim |
Jin Publishing Co., Seoul, Korea |
Website and JATS XML File Producers |
Minyoung Choi |
M2PI, Seoul, Korea |
Yoonsang Cho |
M2PI, Seoul, Korea |
Quality Manager |
Rebecca Ambrose |
Editage, Mumbai, India |
Editorial Assistant |
Jang-Mi Kim |
Korean Society of Neurosonology, Seoul, Korea |
5. Governing Body
The governing body is the editorial board of JNN.
6. Editorial Team and Contact Information
Editor-in-Chief |
---|
Jong-Ho Park | Sungkyunkwan University, Korea |
Associate Editors |
---|
Stroke, Cerebrovascular disease |
Jinkwon Kim | Yonsei University, Korea |
Georgios Tsivgoulis | The University of Tennessee Health Science Center, USA |
Neuromuscular disease |
Jung Im Seok | Catholic University of Daegu, Korea |
Neuroradiology |
Sung Jun Ahn | Yonsei University, Korea |
Editorial Board |
---|
Seong Hwan Ahn | Chosun University, Korea |
Mohammed A Almekhlafi | University of Calgary, Canada |
Claudio Baracchini | University of Padua School of Medicine, Italy |
Adam DeHavenon | Yale School of Medicine, USA |
Michael D. Hill | University of Calgary, Canada |
Jin Hyun Joh | Kyung Hee University Hospital at Gangdong, Korea |
Dae-Hyun Kim | Dong-A University, Korea |
Jongyeol Kim | Texas Tech University Health Sciences Center, USA |
Joon-Tae Kim | Chonnam National University, Korea |
Yerim Kim | Hallym University, Korea |
Christos Krogias | Ruhr University Bochum, Germany |
Hyung-Min Kwon | Seoul National University, Korea |
Yumei Liu | Xuanwu Hospital the Capital Medical University, China |
Branko Malojcic | University Hospital Center Zagreb, Croatia |
Wi Sun Ryu | JLK Inc. Korea |
Mark N Rubin | The University of Tennessee Health Science Center, USA |
Luca Saba | University of Cagliari, Italy |
Woo-Keun Seo | Samsung Medical Center, Korea |
Dong-Ick Shin | Chungbuk National University, Korea |
Sangil Suh | Korea University, Korea |
Kay Sin Tan | University of Malaya, Malaysia |
Joonsang Yoo | Yonsei University, Korea |
Ethics Editor |
---|
Jaseong Koo | The Catholic University of Korea, Korea |
Statistics Editor |
---|
Juneyoung Lee | Korea University, Korea |
Manuscript Editor |
---|
Da Bin Park | Jin Publishing Co., Korea |
Layout Editors |
---|
Mi Jung Kim | Jin Publishing Co., Korea |
Website and JATS XML file producers |
---|
Minyoung Choi | M2PI Co., Korea |
Yoonsang Cho | M2PI Co., Korea |
Quality Manager |
---|
Rebecca Ambrose | Editage, Mumbai, India |
The term of the editor-in-chief shall be at least five years.
The editorial committee is responsible for guidance of the direction of publication content and improvement of JNN quality. For this purpose, the committee is held once or twice a year under the leadership of the editor-in-chief.
- Contact information
-
E-mail: ksn@neurosonology.or.kr
Telephone: +82-2-521-1412
- Editor-in-Chief: Jong-Ho Park, MD, PhD
- Editorial Office
- #1412, 359, Gangnam-daero, Seocho-gu, Seoul, Republic of Korea (ZIP 06621)
Journal of Neurosonology and Neuroimaging
7. Copyright and Licensing
Copyright policy: All published papers become the permanent property of the JNN Editors. Copyrights of all published materials are owned by the JNN Editors. Permission must be obtained from the JNN Editors for any commercial use of materials. Copyright transfer agreement form can be completed by a first author or corresponding author on behalf of all of authors after an agreement.
-
7.1 Licensing information: This is an open-access journal distributed under the terms of the Creative Commons Attribution Non-commercial license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited for non-commercial purpose (http://creativecommons.org/licenses/by-nc/4.0/).
-
7.2   Deposit policy: According to the deposit policy (self-archiving policy) of Sherpa/Romeo(http://www.sherpa.ac.uk/), authors cannot archive pre-print (i.e. pre-refereeing), but they can archive post-print (i.e. final draft post-refereeing). Authors can archive publisher's version/PDF.
8. Author
Neither page charge, article processing fee nor submission fee will be applied. It is the platinum open access journal.
9. Process for Identification and Dealing with Allegations of Research Misconduct
When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are carried out by the Editorial Board.
10. Publication Ethics
-
10.1 Journal policies on authorship and contributorship:
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Every author should meet all of these four conditions. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be agreed by all authors of the paper. Copyright transfer agreement must also be completed by a first author or corresponding author on behalf of all of authors after an agreement.
The JNN does not allow multiple corresponding authors for one article. Only one author should correspond with the editorial office and readers for one article. The JNN does accept notice of equal contribution for the first author when the study was clearly performed by co-first authors.
Correction of authorship after publication: The JNN does not correct authorship after publication unless a mistake has been made by the editorial staff. Authorship may be changed before publication but after submission when an authorship correction is requested by all of authors involved with a manuscript.
-
10.2 Recommendations for working with people with personal connections:
‘People with personal connections’ is defined as minors (age under 19) or researchers’ family members (spouse, offspring, relatives, and so on). Researchers should try to prevent any appearance of research misconduct when involving people with personal connections in research or publishing papers with them.
Best Practice for Researchers
- - Before research starts: Disclose the research activity plan of people with personal connections to their affiliation and their co-investigators.
- - While conducting research: Document and record information, data, and practical knowledge that people with personal connections have produced while doing the research.
- - Before publishing co-authored papers: Notify their affiliations and the journal to which manuscripts will be submitted that people with personal connections participated in the research.
Best Practice for Research Institutes
Research institutes should draft guidelines of regulations for involving people with personal connections in research of publishing a paper with them by including the following guidelines and implementing them.
- - Before research starts: Identify whether people with personal connections will be involved in the research.
- - While conducting research: Guide researchers to document and record information, data, and practical knowledge that people with personal connections have produced while participating in the research.
- - Management of co-authored papers: Establish a database of bibliographies and database of original texts of co-authored papers and monitor them regularly.
Ensure to use Disclosure Form for Involving People with Personal Connections (ENG / KOR) and Pre-release Form for Co-authoring a Publication with People with Personal Connections (ENG / KOR).
-
10.3 Journal policies on conflicts of interest / competing interests:
The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to companies, political pressure from interest groups, and academically related issues. Particularly, all sources of funding applicable to the study should be explicitly stated.
-
10.4 How the journal will handle complaints and appeals:
Open data policy
The policy of the journal is primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from https://publicationethics.org/appeals.
Who complains or makes an appeal?
Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter to editor for the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.
Who is responsible to resolve and handle complaints and appeals?
The Editor, Editorial Board, or Editorial Office is responsible for them.
What may be the consequence of remedy?
It depends on the type or degree of misconduct. The consequence of resolution will follow the guidelines of the Committee of Publication Ethics (COPE).
-
10.5 Sex and Gender Equity in Research (SAGER) guidelines (DOI: 10.1186/s41073-016-0007-6)
Authors should use the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors) carefully to avoid confusing both terms when reporting the sex and/or gender of study participants, the sex of animals or cells. If the study was done involving an exclusive population, for example in only one sex, authors should justify why, except in obvious cases (e.g., prostate cancer for male or ovarian cancer for female). Recommendations per section of the article are as follows.
Title and abstract
If only one sex is included in the study, or if the results of the study are to be applied to only one sex or gender, the title and the abstract should specify the sex of animals or any cells, tissues and other material derived from these and the sex and gender of human participants.
Introduction
Authors should report, where relevant, whether sex and/or gender differences may be expected.
Methods
Authors should report how sex and gender were taken into account in the design of the study, whether they ensured adequate representation of males and females, and justify the reasons for any exclusion of males or females.
Results
Where appropriate, data should be routinely presented disaggregated by sex and gender. Sex- and gender-based analyses should be reported regardless of positive or negative outcome. In clinical trials, data on withdrawals and dropouts should also be reported disaggregated by sex.
Discussion
The potential implications of sex and gender on the study results and analyses should be discussed. If a sex and gender analysis was not conducted, the rationale should be given. Authors should further discuss the implications of the lack of such analysis on the interpretation of the results.
-
10.6 Journal policies on data sharing and reproducibility:
Open data policy
For clarification on result accuracy and reproducibility of the results, raw data or analysis data will be deposited to a public repository, for example, Harvard Dataverse (https://dataverse.harvard.edu/dataverse/) after acceptance of the manuscript. Therefore, submission of the raw data or analysis data is mandatory. If the data is already a public one, its URL site or sources should be disclosed. If data cannot be publicized, it can be negotiated with the editor. If there are any inquiries on depositing data, authors should contact the editorial office.
Clinical data sharing policy
The JNN follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As on July 1, 2018 manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript and updated in the registry record. All the authors of research articles that deal with interventional clinical trials must submit data sharing plan of example 1 to 4 in Table 1. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.
Table 1. Examples of data sharing statements that fulfill these ICMJE requirements*
Element |
Example 1 |
Example 2 |
Example 3 |
Example 4 |
Will individual participant data be available (including data dictionaries)? |
Yes |
Yes |
Yes |
No |
What data in particular will be shared? |
All individual participant data collected during the trial, after deidentification. |
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). |
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). |
Not available |
What other documents will be available? |
Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code |
Study protocol, statistical analysis plan, analytic code |
Study protocol |
Not available |
When will data be available (start and end dates)? |
Immediately following publication. No end date. |
Beginning at 3 months and ending at 5 years following the article publication. |
Beginning at 9 months and ending at 36 months following the article publication. |
Not applicable |
With whom? |
Anyone who wishes to access the data. |
Researchers who provide a methodologically sound proposal. |
Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose. |
Not applicable |
For what types of analyses? |
Any purpose |
To achieve aims in the approved proposal. |
For individual participant data meta-analysis. |
Not applicable |
By what mechanism will data be made available? |
Data are available indefinitely at (link to be included). |
Proposals should be directed to xxx@yyy. To gain access, data requestors will need to sign a data access agreement. |
Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University’s data warehouse but without investigator support other than deposited metadata. |
Not applicable |
|
|
Data are available for 5 years at a third-party website (link to be included). |
Information regarding submitting proposals and accessing data may be found at (link to be provided). |
|
ICMJE = International Committee of Medical Journal Editors.
*These examples are meant to illustrate a range of, but not all, data sharing options.
-
10.7 Journal's policy on ethical oversight: When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
-
10.8 Journal's policy on intellectual property: All published papers become the permanent property of the JNN Editors. Copyrights of all published materials are owned by the JNN Editors.
-
10.9 Journal's options for post-publication discussions and corrections: The post-publication discussion is available through letter to editor as an editorial form. If any readers have a concern on any articles published, they can submit to JNN. If there founds any errors or mistakes in the article, it can be corrected through errata, corrigenda, or retraction.
11. Publishing Schedule
The JNN is published two times a year on the last day of June and December.
Supplementary issues are published by occasional manner.
12. Access
This is an open access journal distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
13. Revenue Sources
Revenue sources of the JNN are supported from the Korean Society of Neurosonology, annual membership fee, and advertising rates.
14. Advertising
The JNN accepts advertisements on the following basis:
-
14.1 Eligibility of the advertised products or services
All products or services should be safe and reliable, and not cause any harm to the health and welfare of humans. Advertisements may promote information and technologies relevant for authors, editors, reviewers, and readers. Pharmaceutical products may also be considered. Advertising is separate from content. Advertisers and sponsors have no advance knowledge of our editorial contents, nor do the editors have advance knowledge of advertisers. Content is never altered, added, or deleted to accommodate advertising. Advertisers and sponsors do not have input regarding any of our editorial decisions or advertising policies. We reserve the right to decline or cancel any advertisement at any time. Advertisements for pharmaceutical products must conform to all regulations and policies of the Ministry of Food and Drug Safety, Republic of Korea in every respect.
-
14.2 Orders
Any individuals or organizations who are interested in advertising their products or services in the print copies of the journal or on its website are encouraged to contact the editorial office. The acceptance of advertisement will be discussed by the editorial board and will be ultimately approved by the publisher.
-
14.3 Disclaimer
Liability: Neither the publisher nor the editors will be legally liable for advertisements presented in the JNN. In addition, they cannot guarantee the accuracy, completeness, or usefulness of the information provided.
Endorsement: The publisher and the editors do not endorse any products or services that are advertised.
Disclaimer: Neither the publisher nor the authors will be legally liable for any of the content of advertisements, so readers must keep this in mind when reading or seeing advertisements.
15. Direct Marketing
Journal propagation has been done through the journal web site and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.
Revision History
Enactment December 1, 2018
Amendment |
December 26, 2019 |
December 21, 2020 |
April 1, 2021 |
|
December 8, 2021 |
November 3, 2022 |
June 22, 2023 |
|
April 20, 2024 |
June 11, 2024 |